All In Biotech

Drug Trial Radar · NCT07109414

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Randomized Phase 2/3 Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

Oct 25, 2028

Study completion Oct 24, 2029

Sponsor

Lead sponsor
Novita Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Gynecologic Oncology Group
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).

Conditions

  • Platinum-resistant Ovarian Cancer

Interventions

  • NP-G2-044Drug

    NP-G2-044 will be provided as a tablet via oral route of administration in the study.

  • PLDDrug

    PLD will be provided as an infusion via intravenous route of administration in the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A (Dose escalation): Number of participants with adverse events (AEs)Time frame: From first dose until Safety Follow-up (30 days ±7 days after last dose of NP-G2-044) Approximately 2 years
  2. Part A (Dose escalation): Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  3. Part B (Dose Optimization): Number of participants with AEsTime frame: From Day 1 until Safety Follow-up (30 days ±7 days after last dose of NP-G2-044) Approximately 2 years
  4. Part B (Dose Optimization): Overall response rate (ORR)Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 2 years)
  5. Part B (Dose Optimization): Progression free survival (PFS)Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 2 years)
  6. Part C (Phase 3): Progression free survival (PFS)Time frame: From randomization until disease progression, death, or withdrawal of consent, whichever occurs first (Approximately 3 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Cancer Care

    Phoenix, Arizona

  • Trials365

    Shreveport, Louisiana

  • Optimum Clinical Research Group, LLC

    Albuquerque, New Mexico

  • University of Pennsylvania Health System, Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • University Of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.